Introduction
Systemic injection of kainic acid (KA), an amino acid L-glutamate analog, causes generalized convulsions leading to disorders involving excitation, excitotoxicity and acute cell death (2) . Glutamate exerts its excitatory action via ionotropic receptors. There are three types of glutamate ionotropic receptors AMPA, kainate and N-methyl-D-aspartate (NMDA). AMPA/kainate receptors are referred as non-NMDA receptors (34, 48, 49) . The neuroexcitant KA can bind to the AMPA/KA receptors, which are subtypes of the ionotropic glutamate receptors in the brain (4) . Binding of glutamate to non-NMDA glutamate receptors causes depolarization of neurons followed by severe status epilepticus (SE), neurodegeneration, plasticity, memory loss and neuronal cell death (18, 53) . KA activates ionotropic glutamate receptors and selectively induces cell death in postsynaptic neurons in the CA3 and CA1 of the hippocampus (2, 20, 38) . KA induces hippocampal cell death through intracellular calcium accumulation (12, 50) . The KA-induced neuronal over-excitation triggers excitotoxicity and Zn 2+ -related acute neuronal cell death in the CA1 and CA3 regions of the hippocampus within a few hours (8, 13, 52) , and this process is followed by a slowly progressing cell death in the same areas that may occur over several days to weeks (51) . This is a possible mechanism by which KA may cause brain damage and seizure. Kainate receptors are highly abundant in the CA3 region, the activation of which can elevate ROS concentration and impair the mitochondrial functions (6, 28, 41) .
Hyperglycemia and hypoglycemia have been considered as keys for the survival or death of neuronal cells in the brain. Numerous studies have suggested that hyperglycemia may result in neuronal cell death and glial damage. Hyperglycemia during ischemia may cause anaerobic glycolysis, which may lead to intracellular acidosis to, in turn, cause an increase in cerebral lactate concentration, finally resulting in neuronal and glial damage (1, 16, 44) . Although the mechanism involved in cell death has not been fully understood, previous studies have demonstrated that hyperglycemia may result in oxidative stress, leading to the release of excitatory neurotransmitters like glutamate, and excitotoxicity in neuronal cells (3, 45) . The direct effect of glycemic control on brain metabolism or the effect of managing systemic glucose concentration in epilepsy has been characterized (31, 40) . However, the exact relationship of seizure-induced hyperglycemia with neuronal cell death has not been understood.
In a recent study, we found that KA administered supraspinally and spinally caused a hyperglycemic effect (21, 22 ). An earlier study has shown that the blood glucose level may influence KA-induced neurotoxicity (19) . Hyperglycemia causes brain damage in models of temporary ischemia and reperfusion (14) , and is also associated with extensive lesions in the neocortex and striatum (33) . We and others have previously reported that KA administration causes hippocampal neuronal cell death (19, 26, 39, 43, 52) . It was reported that systemic injection of KA into hyperglycemic rats shows a higher lethality as well as more severe hippocampal CA1 damage, whereas hypoglycemia protects KA-induced hippocampal CA1 damage (19) . We have recently reported that KA administration increases the blood glucose level and leads to brain damage (21, 22, 39) . We also observed that MK-801 and CNQX blocked the pyramidal cell death in CA3 hippocampal region induced by KA (30) . These findings suggested that both NMDA and non-NMDA receptors are involved in supraspinally administered KA-induced pyramidal cell death in the CA3 region of hippocampus in the mouse (30) . Although we have observed in the same study that supraspinally administered KA induces neuronal cell death in the hippocampal CA3 region, the role of blood glucose on KA-induced neuronal cell death has not yet been characterized. We have hypothesized that KA-induced blood glucose level may be responsible for the KA-induced neuronal cell death, and non-NMDA receptors located spinally or supraspinally may play a significant role. Thus, the effect of a non-NMDA receptor antagonist administered spinally or supraspinally on KA-induced blood glucose level and hippocampal CA3 region cell death was investigated in the present study.
Materials and Methods
All the experiments with animals were approved by the Hallym University Institutional Animal Care and Use Committee (Registration Number: Hallym 2009-05-01). All procedures were conducted in accordance with the 'Guide for Care and Use of Laboratory Animals' published by the National Institutes of Health and the ethical guidelines of the International Association.
Animal
Male ICR mice (MJ Co., Seoul, Korea) weighing 23-25 g were used for all the experiments. The number of animal used was 7-8 for each group. Animals were housed 5 per cage (length × width × height; 10.6 cm × 8.7 cm × 5.2 cm) in a room maintained at 22 ± 0.5°C with an alternating 12 h light-dark cycle. Food and water were available ad libitum. The animals were allowed to adapt to the laboratory for at least 2 h before testing. Experiments were performed during the light phase of the cycle (10:00-17:00). The animals were fasted for 16 h before the tests.
Intraperitoneal (i.p.), Intracerebroventricular (i.c.v.) and Intrathecal (i.t.) Injections
The intraperitoneal (i.p.) injection of KA was conducted to unanesthetized mice. The volume of injection was 250 µl (KA; 15 mg/kg). The i.c.v. administrations of KA and CNQX were performed following the procedure established by Laursen and Belknap (1986) (29) . Each mouse was grasped firmly without anesthesia by the loose skin behind the head. The skin was pulled taut. Each mouse was injected with drug manually at bregma with a 50 µl Hamilton microsyringe fitted with a 26-gauge needle that was inserted to a depth of 2.4 mm. The i.c.v. injection volume was 5 µl, and the injection sites were verified by injecting a similar volume of 1% methylene blue solution, and determining the distribution of the injected dye in the ventricular space. The experiments were performed only when the success rate of i.c.v. injection was over 95%. Intrathecal administration was performed in conscious mice following the method of Hylden and Wilcox (1981) (17) using a 30-gauge needle connected to a 25 µl Hamilton syringe with polyethylene tubing. The i.t. injection volume was 5 µl, and the injection site was verified by injecting a similar volume of 1% methylene blue solution and determining the distribution of the injected dye in the spinal cord. All injections were performed manually at the level of lumber vertebra (L4-L5). The dye injected i.t. was distributed both rostrally and caudally but with a short distance (about 0.5 cm) and no dye was found in the brain. The success rate for the injections was consistently found to be over 95% before the experiments were done.
Cresyl Violet Staining Method and Histological Analysis
After 24 h of KA injection, all mice were transcardially perfused for 30 min. Brain sample was postfixed for 4 h in 4% paraformaldehyde. Brains were cryoprotected in 30% sucrose, the hippocampal area (Bregma, -3.24 mm) was sectioned coronally (45 µm) on a freezing micro-tome and collected in cryoprotectant for storage at -20°C until processed. Sections were rinsed three times for 10 min each in phosphatebuffered saline (PBS) to remove cryoprotectant. Sections were mounted on microscope slides (Fisher) and dried on air. The slide-mounted brain sections were soaked in cresyl violet working solution (0.02% in a buffer solution; 0.2% sodium acetate, 0.3% glacial acetic acid) for 2 min. The slides were then dehydrated through graded ethanol, cleared in histoclear, and coverslipped using Permount (Fisher). Histological analysis method in the pyramidal layer of hippocampal CA3 region was performed under the following procedures. The number of cresyl violet-positive neurons was counted by two blinded observers at the same time using an image i-solution analyzing system equipped with a computer-based CCD camera (Olympus AX70; Center Valley, PA, USA).
Measurement of the Blood Glucose Level
The blood glucose level was measured at 30, 60 and 120 min after KA administration (n = 7-8). The blood was collected as soon as possible with a minimum volume of 1 µl from the tail-vein. The glucose level was measured using the Accu-Chek Performa blood glucose monitoring system (glucometer) (Mannheim, Baden-Württemberg, Germany).
Corticosterone Assay
Four hundred microliters of blood was collected by puncturing the retro-orbital venous plexus. Plasma was separated by centrifugation and stored at −80°C until assayed. Plasma corticosterone levels were determined by the fluorometric determination method (15) .
Insulin ELISA Assay
Using the Mouse Insulin ELISA kit (Shibayagi Co., Ltd. Japan), biotin-conjugated anti-insulin and standards or samples were incubated in monoclonal anti-insulin-coated wells to capture insulin bound with biotin conjugated anti-insulin. After 2 h incubation and washing, HRP (horseradish peroxidase)-conjugated streptavidin was added, and incubated for 30 min. After washing, HRP-conjugated streptavidin remaining in the wells was reacted with a substrate chromogen reagent (TMB) for 20 min, and the reaction was stopped by the addition of an acidic solution, and the absorbance of yellow product was measured spectrophotometrically at 450 nm. The absorbance was directly proportional to the insulin concentration. The standard curve was prepared by plotting absorbance against standard insulin concentrations. Insulin concentrations in the unknown samples were determined using this standard curve.
Adrenalectomy
For adrenalectomy, mice (n = 7) were anesthetized with pentobarbital (120 mg/kg), and bilateral suprarenal fat pad including adrenal glands were removed with forceps after incision of skin and peritoneum. Sham operations were performed with the age-match mice. Following the adrenalectomy surgery, mice were maintained with 0.9% sodium chloride solution. Sham-operated mice were maintained with water. All mice were housed in a room maintained at 22 ± 0.5°C on a 12 h light-dark cycle with food and water available ad libitum. The experiments were performed 6 days after the adrenalectomy procedure. No significant bodyweight change was observed before operation (23.2 ± 0.2 g) and prior to the experiments (23.0 ± 0.3 g). All mice survived after adrenalectomy.
Statistical Analysis
Statistical analysis was carried out by one-way analysis of variance (ANOVA) using GraphPad Prism Version 4.0 for Windows (GraphPad Software, San Diego, CA, USA). P-values less than 0.05 were considered to indicate statistical significance. All values were expressed as the mean ± S.E.M. In our study, the mean blood glucose value of the control group was established through many experiments under matching conditions. Selected mice of the established blood glucose level were then used in replication experiments.
Results
We hypothesized that KA-induced blood glucose level is responsible for the KA-induced neuronal cell death, and non-NMDA receptors may play a significant role in the event. To further study our hypothesis, the effect of KA, administered intraperitoneally, intracerebroventricularly or intrathecally, on the blood glucose and corticosterone levels were examined. The mice were administered once with KA i.p. (15 mg/kg), i.c.v. (0.02 µg/µl; total volume 5 µl) or i.t. (0.02 µg/µl; total volume 5 µl), and the blood glucose level was measured at 30, 60 and 120 min after KA innjection. As shown in Figs. 1, A, B and C, respectively, i.p., i.c.v. or i.t. administration with KA caused the elevations of the blood glucose level. Additionally, the blood corticosterone level was measured 30 min after KA administration. Administration with KA in all three modes caused an elevation of blood corticosterone level (Fig. 1D) . These findings suggest that KA-induced corticosterone level may be resposible for KA-induced elevation of the blood glucose level.
We have previously reported that KA administration causes hippocampal neuronal cell death (26, 39) . To further determine possible involvement of corticosterone, the effect of adrenalectomy on i.c.v.-administered KA-induced hyperglycemia and hippocampal neuronal cell death was examined. Administration of KA by i.c.v. markedly increased the blood glucose level in sham-adrenalectomized mice, whereas the blood glucose level induced by i.c.v.-administered KA was reduced in adrenalectomized mice ( Fig. 2A) . In addition, cell death was examined using the cresyl violet stain 24 h after i.c.v. KA administration at the dose of 0.02 µg/µl, in a total volume of 5 µl, in the hippocampus. Morphological damage induced by KA in the hippocampus was markedly concentrated in the CA3 pyramidal neurons after 24 h (Fig. 2B) . Six days after adrenalectomy, mice were administered i.c.v. with KA (0.02 µg/µl; total volume 5 µl). Adrenalectomy attenuated KA-induced hippocampal CA3 neuronal death (Fig. 2C) . According to these observations, corticosterone up-regulation is responsible for KA-induced hyperglycemia and neuronal cell death.
Several studies have demonstrated that non-NMDA receptors are involved in glucose regulation (23, 27, 35) . We examined further the effects of i.c.v. or i.t. pretreatment with CNQX on systemically administered KA-induced hyperglycemia. Mice were pre- (Fig. 4C ). These observations indicate that CNQX attenuates the KA-induced blood glucose level and increases the corticosterone level in response to maintain normal homeostasis. And these results also suggest that CNQX exerts an anti-diabetic action against KA-induced hyperglycemia by reversing KA-induced hypoinsulinemic action. Taken together, these findings suggest that spinally and supraspinally located non-NMDA receptors are involved in KA-induced hyperglycemia.
Discussion
In the present study, we found that KA administered i.c.v., i.t. or i.p. increased the blood glucose level. The elevation of the blood glucose level induced by KA administered systemically is slightly more pronounced compared to that induced by spinally administered KA. In a recent study, we found that KA administered supraspinally and spinally caused a hyperglycemic effect (21, 22 ). An earlier study has shown that the blood glucose level may influence KA-induced neurotoxicity (19) . Hyperglycemia causes brain damage in models of temporary ischemia and reperfusion (14) and also associated with extensive lesions in the neocortex and striatum (33) . As shown in our present study that the i.c.v. injection of KA increases the corticosterone level and this increase in corticosterone level may further results in hyperglycemia. We propose here that corticosterone may act centrally and peripherally. Centrally injected KA may activate the hypothalamic-pituitary-adrenal axis (HPA axis) and causes an increase in corticosterone by activating the adrenal cortex. The corticosterone may then act on the liver and increase gluconeogenesis. This action further enhances the blood glucose level. Acute hyperglycemia results in the development of most acidic pH as well as higher cerebral lactate concentration, leading to neuronal and glial damage (16, 44) . And another possible mechanism of neuronal cell death is by the direct involvement of glucocorticoid system. Corticosterone may directly cross blood brain barrier to cause neuronal damage. Corticosterone hormones may enter the brain and bind to intracellular glucocorticoid (GC) receptors. The low-affinity GC receptors are distributed throughout the brain whereas mineralocorticoid receptors are highly concentrated in the hippocampus (10) . Several evidences have shown that the cellular vulnerability increases after the activation of glucocorticoid receptors in the hippocampus when combined with additional challenges such as ischemia (36, 42) and preventing the increase in corticosteroid levels during ischemia, and hence preserving cell survival after ischemia preventing seizures (24, 25, 46) . Lee et al., have suggested that glucocorticoids potentiate KAinduced seizures, causing dogs to shiver when they get wet (32) . The glucocorticoid synthesis inhibitor also prevents some forms of seizure-induced hippocampal neuronal damage (47). Elliott et al., have reported that the elevated calcium level stimulates neurotoxic cascades during other energetic insults, and may be a mechanism for the corticosterone-induced hippocampal neuronal vulnerability and toxicity (11) . It was demonstrated that corticosterone exposure during ethanol treatment and/or withdrawal resulted in hippocampal damage, via an activation of glucocorticoid receptors and enhancement of the glutamatergic cascade (37) . However, the cytotoxic mechanism of glucocorticoids in the brain is still unclear. We suggest the possibility that injection of PBS or KA into the brain or spinal cord may activate a cascade of reactions that results in an increase in blood corticosterone level. However, the role of KA on the blood corticosterone level remains to be determined, and according to our findings, KA increases the corticosterone level as compared to PBS. Further to examine the possible role of glucocorticoid system in KA-induced hyperglycemia as well as hippocampal neuronal cell death, the mice were bilaterally adrenalectomized. To confirm the effectiveness of the surgery, we monitored plasma corticosterone level in adrenalectomy (ADX) mice. We observed that corticosterone level was significantly reduced in ADX mice (data not shown). We observed in the present study that the increased blood glucose level induced by KA in the sham-operated group was markedly attenuated in adrenalectomized mice. We also found that the KA-induced neuronal cell death in the CA3 region of the hippocampus was also diminished in ADX mice. These findings suggest that glucocorticoid released from the adrenal gland may play an important role in the regulation of the blood glucose level and hippocampal neuronal cell death induced by KA administered supraspinally.
Several lines of evidence have indicated that the function of NMDA receptors can be regulated by activation of central glucocorticoid receptors. For example, activation of central glucocorticoid receptors has been shown to potentiate NMDA-induced responses in dopamine-sensitive neurons within the ventral tegmental area (7) and to regulate NMDA receptormediated long-term depression (9). However, some previous studies have also suggested that the central and peripheral non-NMDA receptors may be differently involved in the regulation of plasma corticosterone levels (5, 23, 35) . Moreover, in our previous study, we observed that MK-801 and CNQX blocked the pyramidal cell death in the CA3 hippocampal region induced by KA (30) . These findings suggest that both NMDA and non-NMDA receptors are involved in supraspinally administered KA-induced pyramidal cell death in CA3 region of the hippocampus in the mouse (30) . However, the role of the non-NMDA receptor in KA-induced blood glucose regulation is still unclear. To further examine the possible role of non-NMDA receptors in KAinduced hyperglycemia, the effect of CNQX on KA-induced hyperglycemia was investigated. Our finding suggests that the blood glucose level was only slightly enhanced by CNQX when injected i.t. However, i.c.v. or i.t. pretreatment with CNQX significantly attenuated KA-induced hyperglycemia. These findings suggest that systemically administered KA-induced hyperglycemia seems to be associated with the activation of non-NMDA receptors located in the supraspinal or spinal region. Furthermore, supraspinally pretreated CNQX was found to attenuate the hyperglycemic effect induced by KA administered supraspinally. In addition, in the present study, KA administered supraspinally was shown to cause an elevation of the blood corticosterone level whereas the insulin level was down-regulated by KA. These findings suggest that centrally administered KA produces a hyperglycemia by elevating the blood corticosterone and at the same time lowering the blood insulin level. It was also observed that CNQX alone did not affect the plasma insulin level but caused a reversal of KA-induced lowering insulin level, suggesting that CNQX exerts an anti-diabetic action against KAinduced hyperglycemia by reversing KA-induced hypoinsulinemic action. Furthermore, supraspinal treatment with CNQX enhanced the KA-induced blood corticosterone level, suggesting that up-regulation of blood corticosterone level by CNQX may be due to a homeostatic mechanism to maintain the blood glucose level toward the normal level during CNQX-induced lowering effect against KA-induced hyperglycemia.
In conclusion, we found in the present study that KA increases the blood glucose level. A glucocorticoid system appears to play a significant role for KAinduced hyperglycemia as well as hippocampal neuronal cell death. Furthermore, non-NMDA receptors located at the supraspinal level and the spinal cord may be involved in KA-induced hyperglycemia.
